Many Shades Of Evergreen: A Variety Of Legislative Approaches For Preventing The Practice
The Hatch-Enzi-Hagan follow-on biologics amendment to the Senate HELP Committee's health care reform bill contains a provision not present in last year's consensus bill designed to prevent "evergreening," under which brand would be eligible for maximum exclusivity by making only minor changes to products. Evergreening concerns were the primary factor that had prevented reintroduction of last year's bill, and many subsequent pieces of legislation and amendments that attempted to address the issue specified a variety of specific structural elements - such as glycosylation - that would render a product ineligible for data exclusivity.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth